Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thermi, Greece, describes the workshops about risk assessment that will be taking place at ERIC 2020. The first workshop will focus on Tp53 and other genomic abnormalities. The second is on immunoglobulin genes. For clinical management, there are two roundtable discussions. One for frontline treatment and the other for relapsed/refractory chronic lymphocytic leukemia (CLL). There will also be a new workshop focused on minimal residual disease (MRD). This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).